As of 2025-06-10, the Fair Value of Genmab A/S (GMAB.CO) is 519.78 DKK. This value is based on the Peter Lynch's Fair Value formula. With the current market price of 1,438.50 DKK, the upside of Genmab A/S is -63.87%.
With the market price of 1,438.50 DKK and our fair value calculation, Genmab A/S (GMAB.CO) is not a good investment. Investing in GMAB.CO stocks now will result in a potential loss of 63.87%.
Peter Lynch's formula is:
The earnings growth rate we use in the formula is the average growth rate of net income/earnings over the last 5 years. If the average growth rate is smaller than 5%, we set it to 5%. If it is larger than 25%, we set it to 25%. If the TTM EPS is negative, Peter Lynch Fair Value's result can be unreliable.
| Historical Earnings | ||||||
| 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 5Y Avg | |
| Net income | 4,758.00 | 2,957.00 | 830.63 | 663.04 | 1,195.06 | 2,080.75 |
| YoY growth | 119.67% | -37.85% | -71.91% | -20.18% | 80.24% | 13.99% |
| Market Cap (mil) | 92,236.62 |
| P/E | 38.73x |
| Forward P/E | 485.02x |
| EPS | 37.14 |
| Avg earnings growth rate | 13.99% |
| TTM earnings | 2,381.68 |